Oscar Health Inc. shares declined sharply following the release of its second-quarter 2026 financial results, despite the company significantly exceeding analyst forecasts for revenue and earnings. Investor reaction turned negative amid concerns regarding regulatory reviews and potential member churn in the second half of the year.

Quarterly revenue grew by seventy point four percent year-over-year to 4.88 billion dollars compared to the expected 4.74 billion dollars. Adjusted earnings per share reached 1.10 dollars, substantially topping the consensus estimate of 0.38 dollars, while operating margin rose to eight percent, up from minus eight percent in the year-ago period.

The company’s active membership base expanded by forty-six percent to 2.96 million individuals, driven by strong performance in the individual insurance market and adoption of its ICHRA platform. Management also highlighted a record low administrative expense ratio, achieved through the scaling of its proprietary Oswell Agent AI tool for claims processing and care navigation.

Following the release, the stock price dropped to 26.52 dollars from 30.50 dollars, where it was trading immediately prior to the announcement. Primary pressure points included management warnings about doubling monthly churn rates due to CMS eligibility reviews and the need for a cautious outlook on medical cost trends in upcoming periods.